The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Genmab Announces Financial Results for the First Quarter of 2024May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025HighlightsEPKINLY® (epcoritamab) approved by ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc.  a biotechnology company focused on the need ...

Affinity Technologies, Inc. a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...